bromocriptine has been researched along with Dyslipidemia in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Krysiak, R; Okopień, B; Szkróbka, W | 1 |
Carvalho, JC; Conceição, EP; de Oliveira, E; Lima, NS; Lisboa, PC; Moura, EG; Nogueira-Neto, JF; Peixoto-Silva, N | 1 |
Krysiak, R; Okopień, B; Okrzesik, J; Szkrobka, W | 1 |
3 other study(ies) available for bromocriptine and Dyslipidemia
Article | Year |
---|---|
Different effects of fenofibrate on cardiometabolic risk factors in young women with and without hyperprolactinemia.
Topics: Adult; Age Factors; Biomarkers; Bromocriptine; Cardiovascular Diseases; Case-Control Studies; Dopamine Agonists; Dyslipidemias; Female; Fenofibrate; Humans; Hyperprolactinemia; Hypolipidemic Agents; Lipids; Middle Aged; Prolactin; Risk Factors; Sex Factors; Time Factors; Treatment Outcome; Young Adult | 2019 |
Does bromocriptine play a role in decreasing oxidative stress for early weaned programmed obesity?
Topics: Adiposity; Animals; Bromocriptine; Dyslipidemias; Female; Glucose; Injections, Intraperitoneal; Insulin Resistance; Intra-Abdominal Fat; Liver; Liver Diseases; Male; Obesity; Oxidation-Reduction; Oxidative Stress; Prolactin; Rats; Rats, Wistar; Time Factors; Weaning | 2014 |
The effect of fenofibrate on cardiometabolic risk factors in bromocriptine-treated women with mixed dyslipidemia: A pilot study.
Topics: Adult; Blood Glucose; Bromocriptine; Cardiovascular Diseases; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Hypolipidemic Agents; Metabolic Diseases; Middle Aged; Pilot Projects; Risk Factors; Treatment Outcome; Young Adult | 2016 |